Metformina + Sitagliptina Ratiopharm Ratiopharm

Metformin Hydrochloride, the active ingredient in Metformina + Sitagliptina Ratiopharm, is a biguanide presented as a tablet for oral use. It is used to improve glycemic control in adults with type 2 diabetes mellitus, typically as part of a regimen that includes diet and exercise.

GNH USA supplies Metformina + Sitagliptina Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Metformina + Sitagliptina is an oral antidiabetic combination that targets hyperglycemia in type 2 diabetes.

- Type 2 diabetes mellitus: improves blood glucose control as an adjunct to diet and exercise. - Metformin‑intolerant patients: offers an additional glucose‑lowering mechanism when metformin dose is limited. - Inadequate control on metformin monotherapy: adds DPP‑4 inhibition to enhance insulin secretion and reduce glucagon.

Metformina + Sitagliptina may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Headache: mild to moderate intensity. - Upper respiratory symptoms: nasopharyngitis or cough.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic complication. - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe hypersensitivity: skin rash, angioedema, or anaphylaxis.

When prescribing Metformina + Sitagliptina, clinicians should observe several precautionary measures to minimise risk.

- Renal function assessment: evaluate eGFR before initiation and periodically thereafter. - Hepatic impairment: avoid use in patients with significant liver disease due to lactic acidosis risk. - Lactic acidosis risk: discontinue if patient develops severe infection, dehydration, or hypoxia. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks, as safety data are limited. - Concomitant alcohol use: limit intake to reduce lactic acidosis potential. - Store at room temperature: keep in original container, protect from moisture and heat.

Metformina + Sitagliptina can interact with several medicines; some require avoidance while others need careful monitoring.

Major Interactions (Avoid): - Iodinated contrast agents: risk of renal impairment and lactic acidosis; withhold metformin around the procedure. - Cimetidine: may increase metformin plasma concentrations. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise sitagliptin levels.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal function and metformin clearance. - NSAIDs: can impair renal function, increasing metformin accumulation. - Alcohol: enhances risk of lactic acidosis.